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In this review, I summarize some of the early research on NK cell biology and function that
led to the discovery of a totally new receptor system for polymorphic MHC class I mole-
cules.That NK cells both could recognize and kill tumor cells but also normal hematopoietic
cells through expression of MHC class I molecules found a unifying explanation in the
“missing self” hypothesis. This initiated a whole new area of leukocyte receptor research.
The common underlying mechanism was that NK cells expressed receptors that were
inhibited by recognition of unmodified “self” MHC-I molecules. This could explain both
the killing of tumor cells with poor expression of MHC-I molecules and hybrid resistance,
i.e., that F1 hybrid mice sometimes could reject parental bone marrow cells. However, a
contrasting phenomenon termed allogeneic lymphocyte cytotoxicity in rats gave strong
evidence that some of these receptors were activated rather than inhibited by recognition
of polymorphic MHC-I.This was soon followed by molecular identification of both inhibitory
and stimulatory Ly49 receptors in mice and rats and killer cell immunoglobulin-like recep-
tors in humans that could be either inhibited or activated when recognizing their cognate
MHC-I ligand. Since most of these receptors now have been molecularly characterized,
their ligands and the intracellular pathways leading to activation or inhibition identified, we
still lack a more complete understanding of how the repertoire of activating and inhibitory
receptors is formed and how interactions between these receptors for MHC-I molecules
on a single NK cell are integrated to generate a productive immune response. Although
several NK receptor systems have been characterized that recognize MHC-I or MHC-like
molecules, I here concentrate on the repertoires of NK receptors encoded by the nat-
ural killer cell gene complex and designed to recognize polymorphic MHC-I molecules in
rodents, i.e., Ly49 (KLRA) receptors.
Keywords: Ly49 receptors, MHC-I molecules, Rat NK alloreactivity, activating receptors, NK receptor repertoire,
inhibitory receptors, natural killer cells, rat models
INTRODUCTION
Natural killer (NK) cells were originally defined as lymphocytes
with spontaneous reactivity against certain tumor cells. The basis
for recognition and the receptor repertoire they employed were
unknown. The nomenclature was debated, but eventually settled
by Eva Klein and coworkers as NK cells in the mid 1970s (1,
2). Ronald Herberman and coworkers identified them morpho-
logically as large granular lymphocytes (LGL) (3, 4) (Figure 1).
Whether these cells were lymphocytes with unique receptors for
cancer cells or their recognition mechanisms were just byprod-
ucts of unspecific T cell recognition of target cells, was a matter of
debate. At that time, the molecular structure of the TCR and their
cognate MHC ligands were not known.
MOUSE NK CELLS RECOGNIZE POLYMORPHIC MHC-I
LIGANDS VIA A REPERTOIRE OF INHIBITORY RECEPTORS
A contrasting phenomenon also ascribed to NK cells was “hybrid
resistance”described initially by Cudkowitz and Bennett (5–7), i.e.,
irradiated F1 hybrid mice between two inbred “parental” mouse
strains often failed to accept parental bone marrow cell (BMC)
transplants. Certain MHC products, more specifically MHC-I
molecules, were clearly involved (8). However, this form of “rejec-
tion” defied the classical laws of transplantation: F1 hybrid mice
between mice strains differing at the MHC and expressing all the
MHC-I molecules from both parental strains were still able to
“reject” parental BMC. The accumulating body of in vivo exper-
iments indicated unequivocally that this kind of rejection was
mediated by NK cells (9). It became so strong that it stimu-
lated researchers to revise the notion that the immune system
was mainly designed to recognize “foreign” or diseased “self” mol-
ecules. Klas Kärre and Hans-Gustav Ljunggren introduced the
ingenious“missing self”concept of NK recognition (10–12),which
prima facie gave a unifying explanation for both hybrid resistance
and the rejection of tumor cells that had low or absent expres-
sion of their MHC-I molecules. These and later studies rested on
the assumption that NK cells possess a repertoire of inhibitory
receptors expressed on different subpopulations of NK cells and
that these receptors recognize unmodified “self” MHC-I. Hybrid
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FIGURE 1 | Natural killer cells separated from peripheral blood of F344
rats on a Percoll gradient. Note the large azurophilic granule in the
cytoplasm.
resistance could then be explained by the assumption that some
NK cells failed to express inhibitory receptors for MHC-I mol-
ecules from one or the other of the parental strain BMC and
therefore killed them through “missing self.” NK cells can be acti-
vated via a repertoire of receptors for other ligands present on both
normal and neoplastic cells, especially, the NKG2D receptor being
present on all NK cells and recognizing stress induced ligands on
target cells (13). However, the presence of sufficient amounts of
unmodified “self” MHC-I on the cell surface inhibited the NK cell
subset with inhibitory receptors for such ligands from killing (14).
The missing self-hypothesis has over the decades since its con-
ception been substantiated by the detection of a steadily increasing
repertoire of inhibitory NK receptors that can recognize “self”
MHC molecules and also inhibit other activating receptors present
on the same NK cell. Although the complex interplay between acti-
vating and inhibitory receptors has led to several modifications of
the “missing self” hypothesis, the basic concept that NK cell acti-
vation depends on stimulation of activating receptors overriding
inhibitory receptors has emerged from the original concept.
RAT NK CELL ALLOREACTIVITY: A MODEL ORGANISM FOR
STUDYING SOME UNORTHODOX PATTERNS OF NK CELL
ALLORECOGNITION
The missing self-hypothesis in its simplest form was challenged
by a phenomenon first observed in the rat: allogeneic small non-
dividing and recirculating lymphocytes, when injected i.v. into
naïve normal recipients, were sometimes eliminated as soon as
they had left the blood stream (15, 16). MHC genes were clearly
involved (17) but other factors also played a role, since this rapid
elimination was also dependent on genes outside the MHC com-
plex (15, 18, 19). The elimination took place in the lymphoid tissue
(15, 16) more specifically within the T cell areas of lymph nodes
and spleen (20). However, T cells by themselves were not involved
in this acute rejection (see below). This phenomenon, described
extensively in a volume of Immunological Reviews (Elimination of
Allogneic lymphoid cells vol. 73 1983) was termed natural cytotox-
icity by Barbara Heslop (19) or allogeneic lymphocyte cytotoxicity
(ALC) by us (21), emerged from a series of experiments stimulated
by my supervisor William L. Ford at the Dunn School of pathology
in Oxford already in the mid 1970s (15, 22). The intention was to
study the role of MHC compatibility in controlling lymphocyte
recirculation. Since the molecular basis for MHC restriction was
not known at the time, some researchers believed that this restric-
tion might apply also to interactions between lymphocytes and
non-hematopoietic cells. This led further to the idea that the
interaction between small recirculating lymphocytes and the high
endothelial venules (HEV) of the lymphatic tissues, where recir-
culating lymphocytes emigrate from the blood into the lymphoid
tissues, was dependent on MHC compatibility between the lym-
phocytes and the HEV (23, 24). In the spirit of the Gowans/Ford
pioneering studies on lymphocyte recirculation between blood
and lymph (25–27) I conducted a series of experiments where
recirculation of allogeneic lymphocytes was compared with that
of syngeneic lymphocytes in immunologically naïve animals. I
used three different rat strains, all differing at the MHC: PVG, AO,
and DA rats. With appropriate dual radioactive labeling of the cells
the recirculation of allogeneic and syngeneic lymphocytes could
be monitored in the same recipient (15).
What clearly emerged from these studies was that i.v. injected
recirculating lymphocytes entered the lymphoid tissue from the
blood equally well regardless of whether they were MHC compat-
ible or incompatible with the host, i.e., lymphocyte–HEV inter-
actions were not MHC restricted (15). Later autoradiographic
studies substantiated this conclusion (20). However, i.v. injected
allogeneic lymphocytes completely failed to enter the efferent lym-
phatic vessels, i.e., the thoracic duct (15), which normally occurs
between 12 and 24 h after i.v. injection of lymphocytes syngeneic
with the recipient. Presumably, they had been eliminated within
the lymphatic tissues before returning via the main lymphatic ves-
sels to the blood. An in vivo cytotoxic assay was designed to test
this. After injection of 51Cr labeled allogeneic lymphocytes into
rats with an indwelling thoracic duct cannula, they completely
failed to reappear in thoracic duct lymph, but the radioactivity
was instead found in the lymph fluid (28, 29). This assay also
allowed us to study the kinetics of elimination. By monitoring the
radioactivity among recirculating lymphocytes and in lymph fluid
in timed collections from the thoracic duct, we observed evidence
of incipient elimination already within the first 15–30 min after
i.v. injection, i.e., as soon as the lymphocytes had penetrated HEV
and entered the lymphatic tissues, and it was by and large complete
by 24 h (28, 29). Further autoradiographic studies visualized the
site of allogeneic lymphocyte destruction: within the paracortex
of lymph nodes and the PALS of the spleen (20). Since both T
and NK cells are present in these locations, we could not exclude a
contribution of T cells. However, the genetics of ALC and that of
T cell alloreactivity were completely different as alluded to below.
In my first publication (15), I saw some general traits of ALC
and hybrid resistance in mice that led me to postulate already in
1979 that both phenomena might be a manifestation of a com-
mon underlying mechanism assigned to the function of NK cells.
However, there were some notable differences:
• In contrast to hybrid resistance, MHC homozygous inbred
rats sometimes rejected F1 hybrid lymphocytes: e.g., PVG rats
rejected lymphocytes from (PVG×DA)F1 or (PVG×AO)F1
rats almost as well as fully allogeneic DA or AO cells (21, 28). So
the presence of one MHC haplotype identical between the donor
and recipient resulting in exposure of “self” MHC molecules on
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donor cells to the recipient did not guarantee survival of the
injected cells.
• The ALC-mediated rejection was often asymmetric, e.g., PVG
rats rejected DA lymphocytes while there was no rejection in the
other direction (15). Whatever receptor systems were employed,
they diverged highly from the TCR recognition of allogeneic
MHC-I, where strong recognition by CTL in both directions
had been demonstrated.
• In contrast to tumor recognition and hybrid resistance, this form
of rejection was against small non-dividing recirculating lym-
phocytes, indicating that NK cells recognized antigens on highly
differentiated cells and not only tumor cells or multipotent
hematopoietic precursors.
• In contrast to T cell alloreactivity, which is mainly directed
against molecules encoded by the classical MHC-I region termed
RT1-A in the rat, ALC was also controlled elements within the
non-classical class I region termed the RT1-CEM region (17)
(see below).
• Cold target competition studies defined several NK “allospeci-
ficities” determined by the MHC (30–32). Some of the antigens
were present in the area of the rat MHC that does not restrict
T cell responses to conventional antigens, i.e., in the RT1-CEM
region (32–34) (see below). Further experiments identified sev-
eral polymorphic genes in this region that activated NK cells.
This assigned a novel function to this poorly investigated string
of MHC-I genes (35, 36). These MHC-I molecules have about a
10-fold lower expression at the cell surface than classical MHC-I
and had then been disregarded as having functional importance
in classical immune recognition (37).
The strongest evidence that ALC was mediated by NK cells was
obtained from studies in athymic nude rats:
• They are devoid of alloreactive T cells but have increased num-
bers of alloreactive NK cells and eliminated the allogeneic lym-
phocytes via the ALC mechanism more strongly than normal
rats (28).
• Removal of NK cells from these rats with specific antibodies led
to a near complete extinction of ALC (29).
• Removal of B cells and immunoglobulins did not affect ALC
thus ruling out the contribution of alloantibodies (29).
• Unlike adaptive immune responses but similar to NK alloreac-
tivity (NKa) the ALC mechanism did not develop until after the
fourth week of life (29).
My supervisor at the time, William L. Ford strongly urged me
to continue these studies. His ability to look into future was sup-
ported by his statement: “this phenomenon will be of the greatest
biological significance.” Alas, he did not live long enough to see
that his predictions came true.
THE RAT MHC (RT1): GENETIC ORGANIZATION AND ROLE IN
NK ALLOREACTIVITY
In order to understand mechanisms underlying ALC and its rela-
tionship to hybrid resistance, a brief description of the rat MHC
(RT1) is warranted. The RT1 shows several similarities with both
the mouse and human MHC in that it contains regions encod-
ing both MHC-I and II molecules and centrally a class III region
with genes encoding members of the TNF, HSP, and some com-
plement factors (33) (Figure 2). The presence of highly conserved
non-polymorphic framework markers like KE3, Bat 1, and MOG
at certain checkpoints within the MHC in these three species (33)
further indicates that the mouse, rat, and human MHC have devel-
oped from a common ancestor. The rat and mouse MHC resemble
each other in that MHC-I genes are flanking the class II and III
region on each side. However, unlike the mouse, the rat classical
MHC-I molecules restricting T cells to environmental antigens are
located mainly on the centromeric side of the complex (33). Here,
dependent on the rat strain, one, two, or three classical MHC-I
loci are present, each restricting individual T cell responses (38).
Telomeric to the class III region is a string of non-classical class I
genes where the most centromeric part has replaced the H2 D/L in
the mouse. I will concentrate on this region termed RT1-C/E, since
here the polymorphic MHC-I genes relevant for NK allorecogni-
tion are present (32) (Figure 2). Again, there is a great variety
of the number of MHC-I genes present in the RT1-C/E region
between rat strains. In BN rats several genes are present, some are
pseudogenes but most are full length genes, expressible on the cell
surface and some of them can also present peptides (39). However,
their expression at the cell surface is about 10 fold lower than the
classical RT1-A encoded molecules (40).
IN VITRO ASSAYS FOR NK ALLOREACTIVITY: THE NK GENE
COMPLEX
The final proof that NK cells were alloreactive and could be respon-
sible for ALC came with our device of an in vitro test for NK
cell alloreactivity: purified NK cells killed MHC-incompatible
lymphocytes in a standard 4 h in vitro cytotoxic assay (41), and
they specifically recognized gene products encoded by the MHC-
I regions (31, 32). Recognition furthermore showed the same
FIGURE 2 | A comparison between the genetic organization of the
human (HLA), mouse (H2), and rat (RT1) MHC complex. Note that in all
three species genes encoding class I, II, and III molecules are present.
However, their positioning within the MHC are different: the humans lack a
centromeric MHC-I encoding region whereas rats (RT1) lack mouse D/L
homologs telomeric to the class II but instead has a string of genes in the
centromeric part of the RT1.CEM region termed RT1.CE, some of which are
expressed, can present peptides and are also recognized by NK cells.
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patterns as those observed in our ALC experiments, i.e., both clas-
sical (RT1-A) and non-classical (RT1-CE) MHC-I molecules were
targeted (32, 34, 42). However, RT1-A encoded molecules mainly
inhibited ALC and NKa in vitro while RT1-CE encoded molecules
both could either inhibit or stimulate alloreactivity depending on
the rat strain combinations used. Thus, a putative specialization
of classical and non-classical MHC-I regions in control of NKa in
the rat was clearly different from the mouse. Furthermore, a novel
function was assigned to this RT1-CE region.
This initiated a search for receptors on NK cells that could medi-
ate ALC in vitro. Moretta and coworkers had already identified
receptors on human NK cells termed killer cell immunoglobulin-
like receptors (KIR), that upon interaction with MHC-I molecules
inhibited NK reactivity (43, 44). Later KIR receptors activated by
HLA were also identified (45). Karlhofer and Yokoyama identified
a receptor termed Ly49A on mouse NK cells and belonging to the
family of lectin-like receptors encoded by the natural killer cell
gene complex (NKC) (46). This region contains several families of
lectin-like receptors belonging to the type two membrane proteins
with the carboxy terminus extracellularly. It contains receptors
that recognize a multitude of ligands most of which are MHC or
MHC-like. I will in the following concentrate on the Ly49 receptor
family, which is most relevant for understanding the alloreactivity
of NK cells. The interaction between Ly49A and H2Dd inhibited
NK cell from killing the target (47, 48). The Ly49 family of the
NKC was also present in the rat (49) and this led to a search for
Ly49 members that activated rather than inhibited ALC. The iden-
tification of an NKa locus in the rat dominantly controlling ALC
gave additional strong circumstantial evidence for the presence of
activating members of the Ly49 family (49), but we had at the time
no molecular evidence for this.
IDENTIFICATION OF BOTH STIMULATORY AND INHIBITORY
MHC-I RECOGNIZING Ly49 RECEPTORS IN THE RAT
Ironically, the first rat Ly49 member that we molecularly cloned
and functionally characterized was an inhibitory one with an
immuno tyrosine inhibitory motif (ITIM) in its cytoplasmic
domain, indicating inhibition. Its recognition of rat MHC-I mole-
cules was highly specific in that only one of the two classical class I
molecules present in the PVG rat strain, RT1-A1c, was recognized
by the receptor and we called it Ly49i2 (50, 51). Our initial failure
to identify activating Ly49 receptors in the rat was due to the fact
that the cells that we used as transfectants for expression cloning
lacked the adaptor protein DAP12 needed to stimulate activating
downstream pathways for these receptors in NK cells.
However, with the access to the technology needed for coex-
pression of DAP12 and the candidate activating receptor genes, we
eventually identified the first series of activating rat Ly49 receptors
with the mAbs DAR13 or STOK6. One of these receptors, Ly49s3,
was clearly an activating receptor for a non-classical MHC-I RT1-
CE antigen (52, 53). Further research along these lines identified
a repertoire of both activating and inhibitory Ly49 receptors, dif-
ferentially expressed on subpopulations of NK cells (53, 54). This
gave the Ly49 region a central place in rat NKa as it did in mice.
Being beaten time wise by researchers identifying activating
Ly49 receptors for MHC-I molecules in the mouse (55, 56), is rat
NK cell alloreactivity still worth pursuing or do we simply study
“big mice”? We believe no. Although mice and rats have an over-
all superficial similarity in the construction of their NKC with
receptors for both MHC-I and other molecules, the repertoire of
activating rat Ly49 receptors in rats by far outnumbers that in the
mouse (57). Also, the different construction of the MHC between
rats and mice (Figure 2) indicates that the 10–20 million years that
have separated mice and rats from a common ancestor has had
profound effects on the tuning of this part of the innate immune
system. Functionally, rat NK receptors may also have adapted dif-
ferently to the microbial flora the two species have been exposed
to. In mice lacking the adaptor molecule DAP12 associated with
activating Ly49 NK receptors, the innate immune response to the
intracellular bacterium Listeria monocytogenes (LM) is enhanced
(58). In contrast, NK cells have a primary role in early resistance
to LM in the rat (59, 60). Removal of NK cells from the recipi-
ent abrogates the early resistance against LM and athymic nude
rats with increased numbers of alloreactive NK cells eliminate LM
more efficiently than normal rats (59). Again non-classical MHC-
I molecules play a central role, since infection of target cells with
LM led to increased expression of a non-classical MHC-I anti-
gen and this stimulated an activating NK cell receptor (60). It
would be informative to compare complete maps of next gener-
ation sequences (NGS) of the whole NKC in several mouse and
rat strains to pinpoint the regions and mechanisms leading to this
divergence.
INHIBITORY VERSUS ACTIVATING RECEPTORS, WHAT CAME
FIRST, THE HEN OR THE EGG?
In the species where NK receptor repertoires for polymorphic
MHC-I molecules are studied most extensively, there is a strik-
ing pairwise appearance of several of these receptors: some have
almost identical amino acid sequences in their extracellular anti-
gen binding domains but different signaling properties (61). An
intracellular ITIM motif indicates that it is an inhibitory receptor,
while the presence of a charged amino acid in the transmembrane
region (Arginine or Lysine) points to an activating function since
it can bind activating adaptor molecules such as DAP 12. This
suggests that the antigen binding extracellular part of such recep-
tor pairs originates from a common gene. The great resemblance
in both the gene and amino acid sequences of the receptor site
indicates that subtle mechanisms may account for this diversifica-
tion. The prevailing one is that activating receptors arose from
inhibitory ones under pressure by pathogens producing decoy
MHC-like ligands that engaged the inhibitory ones and thus shut
down NK cell recognition though missing self (62, 63). Some of
these activating receptors can recognize such decoy viral peptides
directly such as the MCMV m157 protein recognized by the Ly49H
receptor thus making Ly49H receptor positive mice more resistant
to infection (64). Alternatively, activating receptors may recog-
nize MHC-I molecules directly, but the peptides loaded onto the
MHC-I may be critical for its avidity to the receptor. Certain viral
peptides presented by MHC-I may increase the avidity for binding
to activating KIR (65).
The mechanisms creating the minute differences between
inhibitory and corresponding activating receptors are specula-
tive, but gene conversion, gene duplications, and deletions may
contribute. One mechanism contributing to this close relationship
Frontiers in Immunology | NK Cell Biology June 2014 | Volume 5 | Article 283 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rolstad Rat natural killer cells
is “gene homogenization” described by Fossum and coworkers.
Here, genes encoding the extracellular portion of the receptors
are tightly connected, highly similar or identical, and forced to be
expressed either as activating or inhibitory depending on coupling
to genes encoding the inhibitory or activating transmembrane or
intracellular motifs (66). Gene conversion may be a central mech-
anism here. The mechanisms leading to homogenization are not
known.
Not only at the genetic but also at the functional level the sim-
ilarity between such inhibitory and activating receptor pairs is
striking so that such receptor pairs can recognize the same ligand.
E.g., Ly49A is inhibitory while Ly49D is activating but both bind
to H2Dd in the mouse (48, 67). KIR2DL1 and KIR 2DS1 both
recognize HLA-C2 in humans (68, 69), and the Ly49s5/49i5 pair
can recognize similar non-classical (RT1-CE) MHC ligands in the
rat (54). In mice and humans, sometimes these paired receptors
are expressed in the same NK cells, which may create a problem
in understanding how receptors with identical or similar ligands
but with opposing functions may create a productive immune
response. Our present incomplete knowledge about which mech-
anisms control the differential expression of these receptor systems
in various NK cell subsets and also how the minute differences in
amino acid sequences in the ligand binding site of such receptors
may affect their avidity and binding site for their cognate MHC-I
ligands are items that need to be investigated.
The other issue is that, unlike T cells, each NK cell has a unique
repertoire of both activating and inhibitory receptors, many of
which recognize MHC-I molecules, and this composition varies
between different NK cells. One example is the Ly49 i5 and s5
receptor pair in the rat. They are both expressed in NK cells in
PVG rats, can bind avidly to MHC-I ligands encoded in the RT1-
CE region but are present on different subpopulations of NK cells
and will therefore not cancel each other out (54). A most impor-
tant mechanism for control of the activating NK receptors is that
they may be present, but hyporesponsive unless the NK cell at the
same time expresses enough inhibitory “self” receptors to keep the
activating receptors in check, a phenomenon termed“licensing”or
“education” (70). Only when an activating receptor recognizes an
MHC ligand altered by disease and possibly with higher affinity
than its “healthy” counterpart, could activation override inhibi-
tion. This is an elegant mechanism to avoid autoreactivity of the
activating Ly49 receptors. Here are several challenges for further
research. One is to get a more complete picture of all the Ly49
receptors that NK cells in different mouse or rat strains that rec-
ognize MHC-I ligands. Furthermore, how does a pathogen affect
the expression of MHC-I molecules on an infected target that
may allow NK cell activation to dominate over inhibition? The
diversity of the microbiome of importance for the generation and
maintenance of the innate immune system is far from completely
investigated. Microbial interactions with target cells may alter
their expression of MHC-I and therefore also affect recognition
by activating and inhibitory receptors on NK cells differentially.
Since we do not yet have a complete picture of all the cellular
and molecular events leading to NK cell repertoire formation for
polymorphic MHC-I molecules, the question asked in the head-
ing of this section may be more of a philosophical nature than
one with practical implications, since such activating/inhibitory
pairs of receptors with similar or identical ligand binding sites are
widely distributed throughout the innate immune system (63).
Three possibilities may be considered: (1) activating receptors
evolved from the inhibitory ones under pressure from pathogens as
alluded to above (62) (2) coevolution of activating and inhibitory
receptors, i.e., coupling of the MHC-I binding site of a receptor
to inhibitory or activating motifs could have occurred simultane-
ously, e.g., though homogenization (66). (3) However, whenever
there is formation of an NK receptor repertoire designed to detect
a multitude of foreign invaders, e.g., bacteria or viruses infecting
host cells or otherwise “unhealthy” cells, I presume that activation
will be a primary driving force (35, 66). With increased knowledge
of the evolution of the receptor systems, the control of their expres-
sion in different NK cell subpopulations and how, e.g., microbial
forces have shaped these repertoires in different species, we may
get a more precise view of how this important arm of the innate
immune system was created and finely tuned to protect us from
disease.
BACK TO THE RAT, WHAT ADDITIONAL INFORMATION CAN
THIS SPECIES GIVE US ABOUT THE FUNCTION AND
REGULATION OF NK RECEPTORS FOR POLYMORPHIC MHC-I
MOLECULES?
Given the repertoire of activating Ly49 receptors in the rat and the
polymorphic non-classical MHC-I (RT1-CE) ligands they recog-
nize, I find it unlikely that such a diverse recognition system has
arisen from inhibitory Ly49 receptors alone. How, then, can edu-
cation of such a system be reconciled with a control by inhibitory
Ly49 receptors recognizing classical MHC-I, i.e., licensing? The
fact that activating Ly49 receptors are functional on mature rat
NK cells and need no extra education to immediately recognize
non-classical MHC-I of a different haplotype (54) puts into doubt
that licensing is the only mechanism here. Another possibility is
that non-classical MHC-I (RT1-CE) molecules in the rat being
expressed at a much lower level than the classical RT1-A molecules
(40) leading to so weak recognition by activating Ly49 receptors
that it escapes significant NK cell stimulation and also control
by the inhibitory receptors. Only after infection of a target cell
with, e.g., with Listeria will the RT1-CE ligand be upregulated to
the threshold needed for stimulation (60). Alternatively, infection
may alter the conformation of RT1-CE molecules so that bind-
ing to and activation of Ly49 receptors is enhanced. Nonetheless,
the discovery of a repertoire of activating Ly49 receptors for non-
classical MHC-I molecules in the rat poses a new dimension to
how the Ly49 repertoire has evolved. One consequence of such
repertoire formation, where subgroups of NK cells express acti-
vating Ly49 receptors with different specificities, is that rat NK
cells can be induced into a memory state, i.e., selective expansion
of the subset expressing the receptor for the immunizing ligand.
In a series of experiments conducted by Eva Petersson and
coworkers BN rats (RT1n) immunized i.p. with cells expressing
RT1 of a different MHC haplotype (RT1u) led to selective accumu-
lation in the peritoneum of NK cells with specificity for target cells
expressing a particular non-classical RT1-CEu molecule and not
classical RT1.Au nor to third party MHC molecules. Conversely,
immunization of BN rats with cells expressing RT1c molecules led
to expansion of anti RT1c and not anti RT1u specific NK cells.
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Long lasting immunity was not investigated in these experiments.
However, these experiments showed clearly that alloreactive NK
cells can be subdivided into subsets with activating receptors for
different RT1 alleles. Furthermore, these subsets can be selectively
expanded upon immunization with the cognate MHC ligand in
the RT1-CE region akin to an adaptive immune response (71).
Extended studies along this line has clearly demonstrated long last-
ing specific memory functions among mouse NK cells expressing
activating Ly49 receptors for a virally encoded ligand (72) Such
studies may have implications for vaccination strategies.
Whether the specialized function of the rat RT1-CE encoded
MHC-I molecules in being ligands mainly for NK cell receptors is
unique for the rat or similar regions exist in other species, remains
to be shown. Nevertheless, the formation of a repertoire of acti-
vating Ly49 receptors can pave the path for inducing specific and
possibly long lasting immunological memory among rat NK cells
as it has been shown in the mouse (72).
RAT NK CELLS AND DISEASES
The rat serves as an animal model for several spontaneous or
induced autoimmune diseases like Rheumatoid Arthritis (73, 74),
diabetes (75, 76), autoimmune thyroiditis (77), and multiple scle-
rosis (experimental allergic encephalomyelitis, EAE) (78, 79). The
rat strains where these disease states are present are different from
those used by us: usually LEW, F344, WF, or BB. Their MHC and
NKC with Ly49 genes are not yet fully characterized, so putative
linkage between Ly49 receptor repertoire, expression of specific
MHC-I molecules and disease is not yet achievable. A complete
next generation sequencing of the NKC of these rat strains is
needed to explore this field further. It is, however, noteworthy that
our founder rat strain PVG, having a most extensive repertoire of
both activating and inhibitory Ly49 receptor genes, shows no signs
of either autoimmune diseases or spontaneous tumors.
Another issue pertaining to NK cells in disease is their putative
role as therapeutic targets in allogeneic hematopoietic stem cell
transplantation (HSCT) for the treatment of malignancies, espe-
cially leukemias. We have established a protocol where rats after
myeloablative treatment (irradiation) are transplanted with MHC
mismatched mononuclear BMCs from rat strains with full or par-
tial mismatches for MHC genes, i.e., MHC-I or MHC-II/III genes.
Host NK cells remaining after myeloablation are clearly important
for survival or death of the transplanted HSC, and the mismatches
that lead to failure of the transplanted BMC to engraft are iden-
tical to the mismatches where host NK cells are shown to kill
hematopoietic cells of the donor by the ALC mechanism in vivo
and in vitro. Depending on the haplotype differences between
donor and recipient both classical RT1-A and non-classical RT1-
CE MHC-I regions contribute (80, 81). The implication from these
studies is that in a human alloHSCT setting the HSC donor and
recipient should be chosen so that host alloreactive NK cells do not
recognize MHC-mismatches on the transplanted hematopoietic
cells which will lead to their destruction.
Alloreactivity of the donor-derived NK cells against host
hematopoietic cells may, however, have a beneficial role. There is
accumulating evidence that human patients treated for malignan-
cies with alloHSCT have reduced relapse of the disease if the HSC
are from a donor whose alloreactive NK cells can recognize MHC-I
antigen mismatches in the recipient. This is particularly evident in
the treatment of certain leukemias like AML (82). Initially, this was
assigned to inhibitory KIR of the donor recognizing missing self
MHC ligands in the recipient (82). However, more recent studies
have shown that certain activating KIR like KIR2DS1 recognizing
HLA-C2 may also be beneficial in that they also kill host antigen
presenting cells and T cells and therefore may hinder the devel-
opment of graft-versus-host disease (GVHD), the most serious
complication seen after alloHCST (83–85). The beneficial role of
alloreactive NK cells in both controlling GVH and having a protec-
tive effect against relapse of the leukemia (graft-versus-leukemia,
GVL) has led to ongoing clinical trials where alloHSCT patients
are given allogeneic NK cells as therapeutic tools for avoiding GVH
and promoting GVL.
In our alloHSCT model in the rat, we can test the role of cel-
lular therapy with alloreactive NK cells in preventing GVHD and
in promoting GVL. We have tested the role of alloHCST in con-
trolling an experimentally induced acute rat leukemia in the BN
strain (BNML), resembling human AML (86, 87). Protection was
obtained with repeated alloHSCT, but the mechanisms of protec-
tion are still elusive. Further research along these lines will be to
extend these studies to encompass therapy with alloreactive NK
cells, which are optimally cultured to promote the generation of
a memory phenotype. These studies will be given high priority in
our research group in the years to come.
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